Literature DB >> 21885127

The region of largest β-zone parapapillary atrophy area predicts the location of most rapid visual field progression.

Christopher C Teng1, Carlos Gustavo De Moraes, Tiago S Prata, Craig A Liebmann, Celso Tello, Robert Ritch, Jeffrey M Liebmann.   

Abstract

PURPOSE: To determine if visual field (VF) progression occurs most rapidly in the region of largest β-zone parapapillary atrophy (PPA).
DESIGN: Retrospective cohort. PARTICIPANTS: One hundred twenty-five patients from the New York Glaucoma Progression Study with both β-zone PPA and VF progression.
METHODS: Treated open-angle glaucoma patients with 8 or more Swedish Interactive Threshold Algorithm Standard 24-2 VFs (Humphrey Field Analyzer II; Carl Zeiss Meditec, Inc., Dublin, CA) in either eye were identified. Eyes with optic disc photographs, β-zone PPA, less than 6 diopters myopia, and VF progression were studied. Visual field progression was defined using trend analysis as the presence of at least 2 adjacent progressing points in the same hemifield using standard pointwise linear regression (PLR) criteria. MAIN OUTCOME MEASURES: The correlation between β-zone PPA and location of most rapid future VF progression.
RESULTS: One hundred twenty-five eyes (125 patients; mean age, 71.9 ± 12.3 years; 58% women; 75% European descent) with β-zone PPA and VF progression were enrolled. The mean follow-up was 6.8 ± 1.7 years and the mean number of VFs was 12.5 ± 3.6. Ninety-three patients (74%) had more β-zone PPA inferiorly and 32 patients (26%) had more β-zone PPA superiorly. The fastest VF progression occurred in the superior hemifield in 77 patients (62%) and in the inferior hemifield in 48 (38%) patients. Patients with superior VF progression had a superior localized mean rate of progression of -1.57 ± 1.7 dB/year, and patients with inferior VF progression had an inferior localized mean rate of -0.94 ± 1.4 dB/year (P = 0.012). The mean number of points reaching the predefined PLR end points was 5.6±7.5 for the superior VF hemifield and 3.0±4.9 for the inferior hemifield (P = 0.006). The hemifield with more points reaching PLR progression end points, with fastest average velocity of progression, or both was spatially consistent with the location of largest β-zone PPA in 89 (71%) patients (P = 0.0001, Fisher exact test; κ = 0.35; 95% confidence interval, 0.17-0.53).
CONCLUSIONS: In treated glaucoma patients with β-zone PPA and VF progression, the location of largest β-zone PPA typically correlates spatially with the region of the most rapid future VF progression. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21885127     DOI: 10.1016/j.ophtha.2011.06.014

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  22 in total

1.  Variation of the axial location of Bruch's membrane opening with age, choroidal thickness, and race.

Authors:  John Johnstone; Massimo Fazio; Kulawan Rojananuangnit; Brandon Smith; Mark Clark; Crawford Downs; Cynthia Owsley; Michael J A Girard; Jean Martial Mari; Christopher A Girkin
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-28       Impact factor: 4.799

2.  Association Between Lamina Cribrosa Defects and Progressive Retinal Nerve Fiber Layer Loss in Glaucoma.

Authors:  Sasan Moghimi; Linda M Zangwill; Patricia Isabel C Manalastas; Min Hee Suh; Rafaella C Penteado; Huiyuan Hou; Kyle Hasenstab; Elham Ghahari; Christopher Bowd; Robert N Weinreb
Journal:  JAMA Ophthalmol       Date:  2019-04-01       Impact factor: 7.389

3.  β-Zone Parapapillary Atrophy and Rates of Glaucomatous Visual Field Progression: African Descent and Glaucoma Evaluation Study.

Authors:  C Gustavo De Moraes; James T Murphy; Chad M Kaplan; Jeremy J Reimann; Alon Skaat; Dana M Blumberg; Lama Al-Aswad; George A Cioffi; Christopher A Girkin; Felipe A Medeiros; Robert N Weinreb; Linda Zangwill; Jeffrey M Liebmann
Journal:  JAMA Ophthalmol       Date:  2017-06-01       Impact factor: 7.389

4.  Effect of myopia and age on optic disc margin anatomy within the parapapillary atrophy area.

Authors:  Young Hoon Hwang; Jong Jin Jung; Young Min Park; Yong Yeon Kim; Sungwook Woo; Joo Hwa Lee
Journal:  Jpn J Ophthalmol       Date:  2013-07-13       Impact factor: 2.447

5.  The Topographic Relationship Between Choroidal Microvascular Dropout and Glaucomatous Damage in Primary Angle-Closure Glaucoma.

Authors:  Li Tan; Di Ma; Junren He; Hongxi Wang; Shirong Chen; Yongdong Lin
Journal:  Transl Vis Sci Technol       Date:  2022-10-03       Impact factor: 3.048

6.  Border tissue morphology is associated with the pattern of visual field progression in open-angle glaucoma.

Authors:  Hyun Joo Kee; Jong Chul Han; Eui Do Song; Eui Jun Choi; Dong Ook Son; Eun Jung Lee; Yoon Kyoung Jang; Changwon Kee
Journal:  Sci Rep       Date:  2022-07-14       Impact factor: 4.996

7.  Deformation of Optic Nerve Head and Peripapillary Tissues by Horizontal Duction.

Authors:  Melinda Y Chang; Andrew Shin; Joseph Park; Aaron Nagiel; Robert A Lalane; Steven D Schwartz; Joseph L Demer
Journal:  Am J Ophthalmol       Date:  2016-10-15       Impact factor: 5.258

8.  Predicting the risk of parafoveal scotoma in myopic normal tension glaucoma: role of optic disc tilt and rotation.

Authors:  M S Sung; H Heo; Y S Ji; S W Park
Journal:  Eye (Lond)       Date:  2017-03-10       Impact factor: 3.775

9.  Relationship between disc margin to fovea distance and central visual field defect in normal tension glaucoma.

Authors:  Marvin Lee; Hosung Jin; Jaehong Ahn
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-11-22       Impact factor: 3.117

10.  Detection of progressive macular thickness loss using optical coherence tomography in glaucoma suspect and glaucomatous eyes.

Authors:  P I Niles; D S Greenfield; M Sehi; N Bhardwaj; S M Iverson; Y S Chung
Journal:  Eye (Lond)       Date:  2012-05-11       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.